{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:18:18Z","timestamp":1783052298707,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","award":["AWD#222595"],"award-info":[{"award-number":["AWD#222595"]}],"id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","award":["P30CA46934"],"award-info":[{"award-number":["P30CA46934"]}],"id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1BX004751"],"award-info":[{"award-number":["1BX004751"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"Cancer Center, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cllc.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:13:11Z","timestamp":1777590791000},"page":"96-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"27","author":[{"given":"Yunan","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyse","family":"Staley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trista K.","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Perez-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Merrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtis D.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara L.","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Heasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-1010","authenticated-orcid":false,"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.04.010_bib0001","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations: the lung cancer mutation Consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.010_bib0002","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0004","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2026.04.010_bib0007","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus Crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0008","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus Crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0009","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0011","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0012","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0013","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.010_bib0014","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.010_bib0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.21037\/tlcr-22-883","article-title":"Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions","volume":"12","author":"Schenk","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.010_bib0016","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061476","article-title":"Immunotherapy for ALK-rearranged non-small cell lung cancer: challenges inform promising approaches","volume":"13","author":"Sankar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.04.010_bib0018","article-title":"Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cllc.2026.04.010_bib0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cllc.2026.04.010_bib0021","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2026.04.010_bib0022","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-18-1478","article-title":"Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death","volume":"24","author":"Lu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1951019","article-title":"Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR\/ALK-positive non-small-cell lung cancer","volume":"10","author":"Fang","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cllc.2026.04.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2026.04.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000970","article-title":"Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer","volume":"8","author":"Pyo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41698-023-00355-2","article-title":"Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity","volume":"7","author":"Kleczko","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3","volume":"5","author":"Koh","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cllc.2026.04.010_bib0028","doi-asserted-by":"crossref","first-page":"12487","DOI":"10.1096\/fj.201901343R","article-title":"A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion","volume":"33","author":"Nouri","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.cllc.2026.04.010_bib0029","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0030","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78152-1","article-title":"ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients","volume":"10","author":"Chang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2026.04.010_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060991","article-title":"High PD-L1 expression correlates with an immunosuppressive tumour immune microenvironment and worse prognosis in ALK-rearranged non-small cell lung cancer","volume":"13","author":"Tian","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.cllc.2026.04.010_bib0033","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1634\/theoncologist.2020-0088","article-title":"Association of programmed death-ligand 1 expression with fusion variants and clinical outcomes in patients with anaplastic lymphoma kinase-positive lung adenocarcinoma receiving Crizotinib","volume":"25","author":"Yang","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2026.04.010_bib0034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lungcan.2022.01.006","article-title":"ALK fusion variant 3a\/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)","volume":"165","author":"Li","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107233","article-title":"Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion","volume":"181","author":"Pan","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0036","article-title":"Programmed death-ligand 1 expression in lung cancer and paired brain metastases-a single-center study in 190 patients","volume":"3","author":"K\u00fcndig","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.04.010_bib0037","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/1759-7714.14006","article-title":"Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications","volume":"12","author":"Lee","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC","volume":"19","author":"Lara-Mej\u00eda","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0039","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/2767-9764.CRC-24-0065","article-title":"Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC","volume":"4","author":"Nakazawa","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.cllc.2026.04.010_bib0040","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of Lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations","volume":"18","author":"Bearz","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0041","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1192861","article-title":"Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1\u03b2","volume":"14","author":"Hirayama","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0043","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0044","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/s12967-023-04365-3","article-title":"IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer","volume":"21","author":"Liao","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.cllc.2026.04.010_bib0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2026.04.010_bib0046","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cllc.2026.04.010_bib0047","article-title":"Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer","author":"Kleczko","year":"2022","journal-title":"BioRxiv"},{"key":"10.1016\/j.cllc.2026.04.010_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216062","article-title":"Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response","volume":"556","author":"Kleczko","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2026.04.010_bib0049","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/2159-8290.CD-13-0760","article-title":"Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche","volume":"5","author":"Reticker-Flynn","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.04.010_bib0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2026.04.010_bib0051","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s42003-021-02376-8","article-title":"Neutrophil-derived reactive oxygen species promote tumor colonization","volume":"4","author":"Zhong","year":"2021","journal-title":"Commun Biol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:35:39Z","timestamp":1783049739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525730426000628"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}